Table 4.
Top five pathways (p < 0.01) predicted by IPA for Fayoumi vs. Leghorn in different treatment groups.
| Group | Pathways | Important DEGs contributing to prediction | Ratios |
|---|---|---|---|
| Control 2 dpi | IL-8 signaling | FGFR(1/3), PIK3C(G/2 G),GNG(2/10) | 29/197 |
| Production of nitric oxide and reactive oxygen species in macrophages | PIK3C(G/2 G), FGFR(1/3) , NCF(1/2/4) | 25/193 | |
| STAT3 pathway | PDGFR(A/B), FLT(1/4), FGFR(1/3/L1) | 17/73 | |
| Sumoylation pathway | FAS, FASLG, SENP1, RHOJ , CBX4 | 15/96 | |
| Sphingosine-1-phosphate Signaling | FGFR(1/3), PDGFA, PIK3C(G/2 G) | 17/123 | |
| NDV 2 dpi | mTOR signaling | ATG13, EIF3D/F/L/M, EIF4EBP1 | 35/199 |
| Regulation of eIF4 and p70S6K signaling | PABPC1, EIF3(D/F/L/M), EIF4EBP1 | 29/157 | |
| EIF2 signaling | PABPC1, EIF3(D/F/L/M), EIF2S3 | 36/221 | |
| IL-8 signaling | FGFR(2/3), PIK3C(G/2 G), RHOB | 29/197 | |
| Production of nitric oxide and reactive oxygen species in macrophages | STAT1, PIK3C(G/2 G), FGFR(2/3) | 28/193 | |
| Control 6 dpi | Coagulation system | F7, F10, FGB, SRPINF2, BDKRB1 | 9/35 |
| Leukocyte extravasation signaling | ACT(A1/A2/G2), FGFR(2/3), PIK3C2G | 23/210 | |
| Th2 pathway | PIK3C2G, CD(4/28), FGFR(2/3), DLL1 | 16/150 | |
| Paxilin signaling | ACT(A1/A2/G2), FGFR(2/3), PIK3C2G , | 13/113 | |
| Acute myeloid leukemia signaling | PIK3C2G, KLB, FGFR(2/3), KIT | 11/91 | |
| NDV 6 dpi | Complement system | C1S, C1R, C8B, CFD, MBL2 | 5/37 |
| eNOS signaling | VEGFD, FGFR3, PIK3C2G , CNGA3 | 11/155 | |
| PCP pathway | WNT5A, RSPO3, CELSR1, FZD(3/5) | 6/63 | |
| Oncostatin M signaling | MMP(1/3), PLAU | 4/34 | |
| Coagulation system | SRPINF2, F13A1, PLAU , TFPI | 4/35 |
Note: Bold italic and italic text respectively indicates lower and higher expression of differentially expressed genes (DEGs) in Fayoumi compared to Leghorn. Genes within the same family are labeled with the member or subunit names in the brackets. Ratios = (Number of DEGs in a pathways)/(Total number of genes in the pathway).